Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210

被引：35
|
作者：
Balar, Arjun Vasant
Dreicer, Robert
Loriot, Yohann
Perez-Gracia, Jose Luis
Hoffman-Censits, Jean H.
Petrylak, Daniel Peter
Van Der Heijden, Michiel Simon
Ding, Beiying
Shen, Xiaodong
Rosenberg, Jonathan E.
机构：
[1] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[2] Univ Virginia, Emily Couric Clin Canc Ctr, Charlottesville, VA USA
[3] Gustave Roussy, Villejuif, France
[4] Clin Univ Navarra, Pamplona, Spain
[5] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
[6] Yale Univ, Sch Med, New Haven, CT USA
[7] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[8] Netherlands Canc Inst, Dept Med Oncol, San Francisco, CA USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4523
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
    Siefker-Radtke, Arlene O.
    Necchi, Andrea
    Park, Se Hoon
    Garcia-Donas, Jesus
    Huddart, Robert A.
    Burgess, Earle F.
    Fleming, Mark T.
    Kalebasty, Arash Rezazadeh
    Mellado, Begona
    Varlamov, Sergei
    Joshi, Monika
    Duran, Ignacio
    Tagawa, Scott T.
    Zakharia, Yousef
    Akapame, Sydney
    Santiago-Walker, Ademi E.
    Monga, Manish
    O'Hagan, Anne
    Loriot, Yohann
    LANCET ONCOLOGY, 2022, 23 (02): : 248 - 258
  • [42] Re: Efficacy and Safety of Erdafitinib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: Long-term Follow-upof a Phase 2 Study
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2022, 208 (06): : 1347 - 1349
  • [43] Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
    Bamias, A.
    De Santis, M.
    Arranz, J. A.
    Grande, E.
    Galsky, M. D.
    Kikuchi, E.
    Park, S. H.
    De Giorgi, U.
    Garcia del Muro, X.
    Mencinger, M.
    Alekseev, B.
    Puente, J.
    Izumi, K.
    Gumus, M.
    Mellado Gonzalez, B.
    Li, J-R.
    Quach, C.
    Ding, B.
    Bernhard, S.
    Davis, I. D.
    ANNALS OF ONCOLOGY, 2020, 31 : S551 - S552
  • [44] Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Hoimes, Christopher J.
    Petrylak, Daniel P.
    Flaig, Thomas W.
    Moon, Helen H.
    Friedlander, Terence W.
    Mar, Nataliya
    McKay, Rana R.
    Srinivas, Sandy
    Gravis, Gwenaelle
    Ramamurthy, Chethan
    Bupathi, Manojkumar
    Bracarda, Sergio
    Wright, Phoebe
    Carret, Anne-Sophie
    Yu, Yao
    Matsuda, Tara
    Kataria, Ritesh S.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [45] Patient profiles as drivers of physician choice for first-line (1L) treatment (tx) in locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study.
    Milloy, Neil
    Walley, Maria
    Simpson, Amber
    Forshaw, Cameron
    Morris, Valerie A.
    Kearney, Mairead
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [46] Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
    Balar, A.
    Bellmunt, J.
    O'Donnell, P. H.
    Castellano, D.
    Grivas, P.
    Vuky, J.
    Powles, T.
    Plimack, E. R.
    Hahn, N. M.
    de Wit, R.
    Pang, L.
    Savage, M. J.
    Perini, R.
    Keefe, S.
    Bajorin, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis
    Grande, Enrique
    Bamias, Aristotelis
    Galsky, Matt D.
    Kikuchi, Eiji
    Davis, Ian D.
    Arranz, Jose A.
    Rezazadeh, Arash
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    Lee, Chooi
    Bernhard, Sandrine
    Nicholas, Alan
    Telliez, Julie
    De Santis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.
    Bajorin, Dean F.
    Plimack, Elizabeth R.
    Siefker-Radtke, Arlene O.
    Choueiri, Toni K.
    De Wit, Ronald
    Sonpavde, Guru
    Gipson, Adrianna
    Brown, Holly
    Mai, Yabing
    Pang, Lei
    Perini, Rodolfo F.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve
    Gross-Goupil, Marine
    Domblides, Charlotte
    Lefort, Felix
    Ravaud, Alain
    BULLETIN DU CANCER, 2020, 107 (05) : ES1 - ES7
  • [50] Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
    Schmid, Peter
    Loirat, Delphine
    Savas, Peter
    Espinosa, Enrique
    Boni, Valentina
    Italiano, Antoine
    White, Shane
    Singel, Stina M.
    Withana, Nimali
    Mani, Aruna
    Li, Suwen
    Harris, Adam
    Wongchenko, Matthew
    Sablin, Marie
    CANCER RESEARCH, 2019, 79 (13)
12345